Effect of Bisphosphonates on the Levels of Rankl and Opg in Gingival Crevicular Fluid of Patients With Periodontal Disease and Post-menopausal Osteoporosis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Acta odontológica latinoamericana

• Publication date

  2015-12-01

• Fields of study

  Medicine

• Identifiers
  PMID 27095621
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6.

  2011cited by this paper
• Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss.

  2009cited by this paper
• Inflammation and bone loss in periodontal disease.

  2008cited by this paper
• Risedronate Reduces Osteoclast Precursors and Cytokine Production in Postmenopausal Osteoporotic Women

  2007cited by this paper
• Bisphosphonates: Mode of Action and Pharmacology

  2007cited by this paper
• Downloaded from jdr.sagepub.com at PENNSYLVANIA STATE UNIV on February 23, 2013 For personal use only. No other uses without permission. International and American Associations for Dental ResearchCRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE Bone Remodeling

  2006cited by this paper
• Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients

  2006cited by this paper
• RANKL-RANK signaling in osteoclastogenesis and bone disease.

  2006cited by this paper
• Inflammation-induced Bone Remodeling in Periodontal Disease and the Influence of Post-menopausal Osteoporosis

  2006cited by this paper
• Inflammatory bone destruction and osteoimmunology.

  2005cited by this paper
• Immune Response: The Key to Bone Resorption in Periodontal Disease.

  2005cited by this paper
• The Nitrogen‐Containing Bisphosphonate, Zoledronic Acid, Influences RANKL Expression in Human Osteoblast‐Like Cells by Activating TNF‐α Converting Enzyme (TACE)

  2004cited by this paper
• Levels of cytokine receptor activator of nuclear factor kappaB ligand in gingival crevicular fluid in untreated chronic periodontitis patients.

  2004cited by this paper
• Differential Expression of RANKL and Osteoprotegerin in Gingival Crevicular Fluid of Patients with Periodontitis

  2004cited by this paper
• Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction.

  2003cited by this paper
• Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.

  2003cited by this paper
• Osteoclast differentiation and activation

  2003cited by this paper
• Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

  2002cited by this paper
• Correlates of Osteoprotegerin Levels in Women and Men

  2002cited by this paper
• Bisphosphonates and periodontics: potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses.

  2002cited by this paper
• Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression

  2002cited by this paper
• Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts.

  2001cited by this paper
• Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology

  2001cited by this paper
• Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection.

  2000cited by this paper
• Bisphosphonates: from the laboratory to the clinic and back again.

  1999cited by this paper
• Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells.

  1999cited by this paper
• Development of a classification system for periodontal diseases and conditions.

  1999cited by this paper
• Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

  1998cited by this paper
• The pathogenesis of human periodontitis: an introduction.

  1997cited by this paper
• Osteoclast activation: Potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism

  1997cited by this paper
• Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption.

  1996cited by this paper
• Bleeding on probing. A parameter for monitoring periodontal conditions in clinical practice.

  1994cited by this paper
• Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.

  1993cited by this paper

• Orthodontics and Bisphosphonates: Risks, Limitations, and Considerations: A Narrative Review

  2025cites this paper
• The effect of cold atmospheric plasma on viability of osteoblasts and expression of RANKL and OPG genes in medium with bisphosphonates

  2024cites this paper
• The Pathogenetic Role of RANK/RANKL/OPG Signaling in Osteoarthritis and Related Targeted Therapies

  2024cites this paper
• Effect of periostin on bone metabolic and autophagy factors during tooth eruption in mice

  2023cites this paper
• Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study

  2023cites this paper
• Astragalus polysaccharide alleviates alveolar bone destruction by regulating local osteoclastogenesis during periodontitis.

  2021cites this paper
• Effect of periostin silencing on Runx2, RANKL and OPG expression in osteoblasts

  2020cites this paper
• Tumour dormancy in inflammatory microenvironment: A promising therapeutic strategy for cancer-related bone metastasis

  2020cites this paper
• A new anabolic compound, LLP2A-Ale, reserves periodontal bone loss in mice through augmentation of bone formation

  2020cites this paper
• Bisphosphonates Reduce Smoking-Induced Osteoporotic-Like Alterations by Regulating RANKL/OPG in an Osteoblast and Osteoclast Co-Culture Model

  2020cites this paper
• OCY 454 Osteocytes as an in Vitro Cell Model for Bone Remodeling Under Mechanical Loading

  2019cites this paper
• OCY454 Osteocytes as an in Vitro Cell Model for Bone Remodeling Under Mechanical Loading

  2019cites this paper
• Improved RANKL expression and osteoclastogenesis induction of CD27+CD38- memory B cells: A link between B cells and alveolar bone damage in periodontitis.

  2018cites this paper
• Recent advances in periodontitis, a prototypic osteo-immunological disease

  2018cites this paper
• Effect of Alendronate Treatment on Salivary Levels of Osteoprotegrin and TNF-α in Postmenopausal Woman with Osteoporosis and Periodontal Diseases

  2018cites this paper
• Investigating the Effects of Systemically Administered Strontium Ranelate on Alveolar Bone Loss Histomorphometrically and Histopathologically on Experimental Periodontitis in Rats

  2017cites this paper
• Effect of bisphosphonate as an adjunct treatment for chronic periodontitis on gingival crevicuar fluid levels of nuclear factor-κB ligand (RANKL) and osteoprotegerin in postmenopausal osteoporosis.

  2017cites this paper
• Administration of RANKL boosts thymic regeneration upon bone marrow transplantation

  2017cites this paper